Functional activated protein C resistance assays: Correlation with factor V DNA analysis is better with RVVT- than APTT-based assays

British Journal of Biomedical Science

Volumn 56, Issue 1, 1999, Pages 23-33

  Favaloro, Emmanuel J ^a   Mirochnik, Oksana ^a   McDonald, David ^a  

^a Inst of Clin Pathol and Med Res   (Australia)

Author keywords

Diagnosis; Factor V Leiden; Laboratory techniques and procedures; Partial thromboplastin time; Protein C; Prothrombin time

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; DILUENT; DNA; PROTEIN C; SNAKE VENOM;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; GENE MUTATION; HETEROZYGOTE; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; SNAKE; THROMBOPHILIA;

FACTOR V; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTHROMBIN TIME; THROMBOPHILIA;

SERPENTES; VIPER;

EID: 0032927431     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-8.
2. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82:1989-93.
3. Koster T, Rosendaal F, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342:1503-6.
4. Stevsson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-22.
5. Cadroy Y, Sie P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Letters to the editor. Blood 1994; 83:2008-9.
6. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 69:64-7.
7. 506 of factor V. Lancet 1994; 343:1535-6.
8. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343:1536-8.
9. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94:2521-4.
10. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 6:1504-8.
11. Zehnder JL, Benson RC. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Am J Clin Pathol 1996; 106:107-11.
12. Voelkerding KV, Wu L, Williams EC et al. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. Am J Clin Pathol 1996; 106:101-6.
13. Wasserman LM, Edson JR, Key NS, Chibbar R, McGlennen RC. Detection of the factor V Leiden mutation, development of a testing algorithm combining a coagulation assay and molecular diagnosis. Am J Clin Pathol 1997; 108:427-33.
14. 506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73:739-42.
15. Jorquera JI, Montoro JM, Fernandez MA. Modified test for activated protein C resistance. Letters to the editor. Lancet 1994; 344:1162-3.
16. Trossaert M, Conard J, Horellou MH. Modified APC resistance assay for patients on oral anticoagulant therapy. Letters to the editor. Lancet 1994; 344:1709.
17. Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Letters to the editor. Thromb Haemost 1995; 73:732-3.
18. 506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Letters to the editor. Thromb Haemost 1995; 73:734-5.
19. Kapiotis S, Quehenberger P, Jilma B et al. Improved characteristics of APC-R assay: Coatest APC resistance by predilution of samples with factor V deficient plasma. Am J Clin Pathol 1996; 106:588-93.
20. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72:880-6.
21. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74:449-53.
22. Aboud MR, Ma DDF. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Br J Haematol 1996; 97:798-803.
23. Florell SR, Rodgers GM. Utilization of testing for activated protein C resistance in a reference laboratory. Am J Clin Pathol 1996; 106:248-52.
24. Ma DDF, Williams BG, Aboud MR, Ibister JP. Activated protein C resistance (APC) and inherited factor V (FV) missense mutation in patients with venous and arterial thrombosis in a haematology clinic. Aust NZ J Med 1995; 25:151-4.
25. Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV:Q506 mutation - evaluation of thirteen plasma based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77:436-9.